Importance of the field: The inactive NF-κB–inhibitor of NF-κB (IκB) complex is activated by stimuli including pro-inflammatory cytokines, mitogens, growth factors and stress-inducing agents. The release of NF-κB facilitates its translocation to the nucleus, where it promotes cell survival by initiating transcription of genes encoding stress-response enzymes, cell-adhesion molecules, pro-inflammatory cytokines and anti-apoptotic proteins. NF-κB and associated regulatory factors (IκB kinase subunits and bcl-3) are implicated in hematological and solid tumour malignancies. NF-κB appears to be involved in cell proliferation control, apoptosis control, angiogenesis promotion and possibly regulation of diffusion of metastases. There are several reports that inhibition of NF-κB as a therapeutic target may have a role in tumour cell death or growth inhibition. Area covered in this review: We review data about inhibition of NF-κB in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). We describe the molecular mechanisms underlying NF-κB deregulation in these haematological malignancies. What the reader will gain: Constitutive activation of NF-κB in the nucleus has been reported in some varieties of MDS/AML. The in vitro and in vivo results of NF-κB inhibition in myeloid malignancies are highlighted. Take home message: NF-κB selective inhibitory drugs may be useful, either as single agents or associated with conventional chemotherapy. Read More: http://informahealthcare.com/doi/abs/10.1517/14728222.2010.522570
NF-KB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia / Breccia, M; Alimena, Giuliana. - In: EXPERT OPINION ON THERAPEUTIC TARGETS. - ISSN 1472-8222. - STAMPA. - 14:(2010), pp. 1157-1176. [10.1517/14728222.2010.522570]
NF-KB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia.
Breccia M;ALIMENA, Giuliana
2010
Abstract
Importance of the field: The inactive NF-κB–inhibitor of NF-κB (IκB) complex is activated by stimuli including pro-inflammatory cytokines, mitogens, growth factors and stress-inducing agents. The release of NF-κB facilitates its translocation to the nucleus, where it promotes cell survival by initiating transcription of genes encoding stress-response enzymes, cell-adhesion molecules, pro-inflammatory cytokines and anti-apoptotic proteins. NF-κB and associated regulatory factors (IκB kinase subunits and bcl-3) are implicated in hematological and solid tumour malignancies. NF-κB appears to be involved in cell proliferation control, apoptosis control, angiogenesis promotion and possibly regulation of diffusion of metastases. There are several reports that inhibition of NF-κB as a therapeutic target may have a role in tumour cell death or growth inhibition. Area covered in this review: We review data about inhibition of NF-κB in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). We describe the molecular mechanisms underlying NF-κB deregulation in these haematological malignancies. What the reader will gain: Constitutive activation of NF-κB in the nucleus has been reported in some varieties of MDS/AML. The in vitro and in vivo results of NF-κB inhibition in myeloid malignancies are highlighted. Take home message: NF-κB selective inhibitory drugs may be useful, either as single agents or associated with conventional chemotherapy. Read More: http://informahealthcare.com/doi/abs/10.1517/14728222.2010.522570I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.